- Home
- BLND vs CVAC Comparison
BLND vs CVAC Comparison
Compare BLND & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLND
- CVAC
- Stock Information
- Founded
- BLND 2012
- CVAC 2000
- Country
- BLND United States
- CVAC Germany
- Employees
- BLND N/A
- CVAC N/A
- Industry
- BLND EDP Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BLND Technology
- CVAC Health Care
- Exchange
- BLND Nasdaq
- CVAC Nasdaq
- Market Cap
- BLND 815.3M
- CVAC 818.8M
- IPO Year
- BLND 2021
- CVAC 2020
- Fundamental
- Price
- BLND $3.61
- CVAC $3.37
- Analyst Decision
- BLND Buy
- CVAC Strong Buy
- Analyst Count
- BLND 7
- CVAC 2
- Target Price
- BLND $4.84
- CVAC $14.00
- AVG Volume (30 Days)
- BLND 2.4M
- CVAC 532.3K
- Earning Date
- BLND 05-08-2025
- CVAC 05-27-2025
- Dividend Yield
- BLND N/A
- CVAC N/A
- EPS Growth
- BLND N/A
- CVAC N/A
- EPS
- BLND N/A
- CVAC 0.75
- Revenue
- BLND $164,949,000.00
- CVAC $554,073,921.00
- Revenue This Year
- BLND $15.07
- CVAC N/A
- Revenue Next Year
- BLND $21.95
- CVAC $37.79
- P/E Ratio
- BLND N/A
- CVAC $4.55
- Revenue Growth
- BLND 15.07
- CVAC 895.54
- 52 Week Low
- BLND $2.08
- CVAC $2.22
- 52 Week High
- BLND $5.53
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- BLND 63.71
- CVAC 51.56
- Support Level
- BLND $3.14
- CVAC $3.26
- Resistance Level
- BLND $3.66
- CVAC $3.70
- Average True Range (ATR)
- BLND 0.14
- CVAC 0.23
- MACD
- BLND 0.05
- CVAC -0.01
- Stochastic Oscillator
- BLND 87.74
- CVAC 29.01
About BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.